Starlynn Clarke

Director, Preclinical Biology

Professional Overview
Starlynn Clarke is a seasoned leader in the biopharmaceutical industry, with extensive expertise in preclinical biology. As the Director of Preclinical Biology at Rondo Therapeutics, she oversees a team of scientists responsible for advancing novel therapeutic candidates from discovery to early-stage development.

Experience Summary

Current Role
As the Director of Preclinical Biology at Rondo Therapeutics, Starlynn is responsible for leading a team of scientists in the design, execution, and analysis of in vitro and in vivo studies to support the preclinical development of the company's drug pipeline. She plays a pivotal role in ensuring the successful progression of candidate molecules through the preclinical stage, contributing to the development of therapeutic solutions that have the potential to address unmet medical needs.

Career Progression
Prior to her current role, Starlynn held positions of increasing responsibility in the field of preclinical biology, including Senior Scientist II at Rondo Therapeutics, Senior Scientist and Scientist at Frontier Medicines, and Research Scientist at Teneobio, Inc. (acquired by Amgen). Throughout her career, she has demonstrated a strong track record of driving research initiatives, fostering collaborative partnerships, and delivering meaningful contributions to the advancement of innovative therapies.

Academic Background
Starlynn holds a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, where she specialized in understanding the underlying molecular mechanisms of disease processes. Her academic achievements include the prestigious Amgen Scholarship, which she earned during her undergraduate studies at UC Irvine.

Areas of Expertise
Starlynn's areas of expertise include preclinical study design, in vitro and in vivo disease modeling, biomarker identification, and the application of cutting-edge analytical techniques to support drug discovery and development. She is also skilled in leading cross-functional teams, fostering collaborative partnerships, and effectively communicating scientific findings to diverse stakeholders.

Professional Impact
Throughout her career, Starlynn has made significant contributions to the advancement of novel therapeutic candidates. Notable achievements include her work on a first-in-class small molecule inhibitor that successfully progressed through preclinical development and is now in clinical trials, as well as her leadership in the development of a proprietary platform for the identification of novel drug targets.

Conclusion
With her extensive experience in preclinical biology, strong scientific acumen, and collaborative leadership style, Starlynn Clarke is poised to drive continued innovation and progress in the biopharmaceutical industry. As the Director of Preclinical Biology at Rondo Therapeutics, she is committed to advancing the company's drug pipeline and contributing to the development of transformative therapies that improve patient outcomes.